Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD Clinical Trial
Official title:
A Phase IV, Randomised, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by
the definition of disease activity, which determines the treatment interval until the next
injection. The results will be used to generate recommendations about ranibizumab treatment
when using an 'inject and extend' approach to maximise patient outcomes, while reducing the
need for potentially unnecessary intravitreal injections. This study will also investigate if
genotypic expression influences response to intravitreal injections of ranibizumab between
the two treatment arms.
The study hypothesis is that intravitreal ranibizumab when administered to resolve IRF
(and/or SRF >200 μm at the foveal centre) results in visual acuity benefit that is not
clinically worse than intravitreal ranibizumab when administered to completely resolve both
IRF and SRF in patients with wet AMD
n/a